**Appendix 2. Eligibility criteria**

|  |  |  |
| --- | --- | --- |
|  | Inclusion criteria | Exclusion criteria |
| Population | ESKD patients undergoing PD |  |
| Intervention | Measurement of IPP  Calculation of eIPP | Using methods other than Durand's method to measure the IPP  No IPP/eIPP mentioned in the study  Radiological or radio nuclear imaging |
| Outcome | Primary:  Variables showing statistically significant relationships with IPP or eIPP  Secondary: Clinical outcomes related to leaks:   * Pleuro-peritoneal fistula (PPF) * Patent processus vaginalis (PPV) * Hernias * Retroperitoneal leak   Clinical measured or patient reported gastrointestinal symptoms  Ultrafiltration volume change  Change of dialysis modality to haemodialysis (HD) | Peritonitis  Cardiovascular complications  Malnutrition  Anaemia  Pharmacokinetics  Pharmacodynamics |
| Study type | Randomized or non-randomized controlled trials  Prospective or retrospective observational studies | Any trials described as pilot studies  Animal studies  Systematic reviews  Literature reviews  Editorials, letters, and commentaries  Conference abstracts |
| Others | Language: English and Chinese  Published from 1/1/1990 to 31/3/2024  Study duration: ≥ 12 weeks | Other languages  Study duration: < 12 weeks |